Avenanthramides and atheroprotection This is from 2014 and demonstrates the interest...
CZO has now created the first potent, pharma-grade pill and received Health Canada approval to test avenanthramides at high doses and test different dosing regimens.
"New research shows that oat AVEs may be partly responsible for the positive association between oats and heart health. Oliver Chen, Ph.D., of the Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, presented mechanistic data that demonstrated that the antioxidant and anti-inflammatory properties of AVEs likely contribute to the atheroprotection of oats.
Similarly, Mohsen Meydani, Ph.D., from the Vascular Biology Laboratory at the Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, provided evidence that oat AVEs suppress the production of inflammatory cytokines associated with fatty streak formation in the arteries. In addition, oat AVEs appear to repress the process associated with the development of atherosclerosis.
"On behalf of the Quaker Oats Center of Excellence, we are inspired by the investigations in oats agriculture, processing and health research presented at the American Chemical Society's Scientific Sessions," comments YiFang Chu, Ph.D., PepsiCo R&D Nutrition. "Along with all of the oats fans out there, we value the significant contribution of scientific collaboration to help expand the thinking behind oats.""
Research: New Reason To Eat Oats For Heart Health (nutritioninsight.com)